7 FDA-Approved CAR T-Cell Therapies Advancing Cancer Treatment

Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary form of immunotherapy that has shown significant promise in treating various types of cancer, particularly hematologic malignancies such as leukemia and lymphoma. This therapy involves genetically engineering a patient's T-cells to express receptors specifically targeting and destroying cancer cells.

Market Overview

According to BCC Research, the global market for CAR T-cell therapy is expected to increase significantly. In 2024, it was valued at approximately $4.6 billion and is projected to reach $25.1 billion by the end of 2029, growing at a compound annual growth rate (CAGR) of 40.2%. This impressive growth is driven by several factors, including the increasing incidence of cancer, the Growing significance of precision medicine, and Growing investments and funding in CAR T-cell therapy research.

Picture1-Apr-17-2025-10-51-04-0952-AM

7 FDA-Approved Therapies in the CAR T-Cell Therapy Market

Kymriah (Tisagenlecleucel): The first CAR T-cell therapy approved by the FDA in 2017, Kymriah is used to treat pediatric and young adult patients with refractory or relapsed B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed or refractory large B-cell lymphoma. Novartis has pioneered the CAR T-cell therapy space, collaborating with the University of Pennsylvania to develop this groundbreaking treatment.
Yescarta (Axicabtagene Ciloleucel): Approved by the FDA in 2017, Yescarta treats adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Kite Pharma has been instrumental in advancing CAR T-cell therapies and continues to innovate in this field.
Tecartus (Brexucabtagene Autoleucel): Approved in 2020, Tecartus is indicated for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL). This therapy represents a significant advancement for patients with this challenging type of lymphoma.
Breyanzi (Lisocabtagene Maraleucel): Approved by the FDA in 2021, Breyanzi treats adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. BMS acquired Juno Therapeutics, the original developer of Breyanzi, further strengthening its position in the CAR T-cell therapy market.
Abecma (Idecabtagene Vicleucel): Approved in 2021, Abecma is the first CAR T-cell therapy for the treatment of multiple myeloma. Developed in partnership with bluebird bio, Abecma offers a new treatment option for patients with this difficult-to-treat cancer.
Carvykti (Ciltacabtagene Autoleucel): Approved by the FDA in 2022, Carvykti is used to treat adult patients with relapsed or refractory multiple myeloma. This therapy results from a collaboration between Legend Biotech and Janssen Biotech, showcasing the power of strategic partnerships in advancing CAR T-cell therapies.
Aucatzyl: Autolus Therapeutics is developing Aucatzyl, a CAR T-cell therapy targeting various hematologic malignancies. Although still in clinical trials, Aucatzyl represents a promising addition to the CAR T-cell therapy landscape.

Recent Developments and Innovations

In Vivo CAR T-cell Innovations: Vyriad has partnered with Novartis to explore in vivo CAR T-cell therapies, which involve modifying T-cells directly within the patient's body. This approach aims to simplify the manufacturing process and potentially reduce costs.
New Clinical Trials: The number of clinical trials for CAR T-cell therapies continues to rise, with the United States and China leading in the number of registered trials. These trials are crucial for expanding the indications and improving the efficacy and safety of CAR T-cell therapies.
Collaborations and Partnerships: Institutions like Moffitt Cancer Center and AstraZeneca are collaborating to accelerate the development of CAR T-cell therapies. These partnerships are essential for driving innovation and bringing new therapies to market.

Conclusion

The CAR T-cell therapy market is characterized by quick developments and significant contributions from major pharmaceutical and biotech firms. With continuous research and development, these therapies hold the potential to transform cancer treatment and offer new hope to patients worldwide.

Learn More and Take Action:

Consider becoming a member of the BCC Research Library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.